RBC Capital analyst Randall Stanicky maintained a Hold rating on Teva Pharmaceutical on Wednesday, setting a price target of $11, which is approximately 1.08% below the present share price of $11.12.
Stanicky expects Teva Pharmaceutical to post earnings per share (EPS) of $0.14 for the first quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Hold rating of shares in Teva Pharmaceutical, with an average price target of $11.67.
The analysts price targets range from a high of $15 to a low of $9.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $4.45 billion and a net profit of $745 million. The company's market cap is $12.19 billion.
According to TipRanks.com, RBC Capital analyst Randall Stanicky is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of 0.0% and a 40.89% success rate.
Teva Pharmaceutical Industries (NYSE:TEVA) Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.